Clinical Trial Update: Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer [Phase 1]

View source ↗

Summary

A Biogen-sponsored Phase 1 study evaluating gemcitabine with RTA 402 (bardoxolone methyl) in patients with unresectable pancreatic cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• RTA 402 (bardoxolone methyl) (bardoxolone methyl)

Snippet

Sponsor: Biogen | Conditions: Pancreatic Neoplasms, Pancreatic Cancer | Phase 1 | Status: TERMINATED